This site is still under development. Information, features, and some organizational
aspects of the data still need further work and will change as we continue building.

Gonzalez Protocol

The Gonzalez Protocol is an individualized nutritional-enzyme cancer regimen developed by Nicholas J. Gonzalez, MD, building on William Donald Kelley’s enzyme therapy and John Beard’s trophoblast theory of cancer. It combines metabolic typing, individualized diets, large numbers of supplements, oral freeze-dried porcine pancreatic enzymes, and detoxification routines such as coffee enemas. The protocol is controversial.

Description

Overview

The Gonzalez Protocol is a highly individualized alternative cancer program developed by Nicholas James Gonzalez, MD (December 28, 1947 - July 21, 2015). It grew from Gonzalez’s investigation of William Donald Kelley’s nutritional-enzyme approach and from older theories by John Beard about trophoblast cells, pancreatic enzymes, and cancer. Gonzalez practiced in New York and described his method as a metabolic, nutritional, detoxification, and enzyme-based program rather than a single supplement.

Main components

The regimen commonly includes a prescribed metabolic-type diet, large supplement schedules, freeze-dried porcine pancreatic enzymes for cancer patients, glandular products, vitamins/minerals, and detoxification procedures. Public descriptions of the program often note 130-200 capsules per day, individualized diets ranging from near-vegetarian patterns to meat-heavy patterns, and coffee enemas, often twice daily.

Cancer rationale

The central cancer claim is that pancreatic proteolytic enzymes can help break down or control cancer cells, while individualized diet and supplements correct autonomic nervous system imbalance and improve host terrain. Gonzalez linked this to the trophoblast theory of cancer, arguing that pancreatic enzymes may normally regulate trophoblast-like invasive cell behavior. Conventional sources characterize these mechanisms as unproven for cancer treatment.

Evidence record

A 1999 Nutrition and Cancer pilot study by Gonzalez and Linda Isaacs reported unusually long survival among a small group of inoperable pancreatic adenocarcinoma patients treated in their practice, but it was uncontrolled and small. A later NIH/NCI-linked nonrandomized controlled trial comparing pancreatic enzyme therapy plus specialized diet with gemcitabine in inoperable pancreatic cancer reported substantially worse survival and quality-of-life outcomes for the enzyme-regimen group. Gonzalez later disputed the conduct and interpretation of the trial in his book What Went Wrong.

Safety and practical concerns

The program can be complex and burdensome, with large numbers of pills, restrictive diet requirements, detox routines, and potential risks from coffee enemas, nutritional imbalance, delayed conventional care, supplement interactions, and disease-related malnutrition. It should be presented with both sides: the case-history/proponent literature and the conventional trial/NCI/CancerChoices critiques.

Kelley Enzyme Therapy Connection

William Donald Kelley’s nutritional-enzyme therapy is preserved here as a precursor and related tradition. Gonzalez studied Kelley’s cancer case files, wrote One Man Alone about that investigation, and developed his own more formal individualized protocol from that foundation.

All Protocols